ライフサイエンスコーパス: Rous sarcoma

1 rowth Factor Receptor Substrate 2 (Frs2) and Rous sarcoma oncogene (Src) Homology Phosphatase 2 (Shp2

2 cytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity.

3 at Y951 facilitates binding of VEGFR2 to the Rous sarcoma (Src) homology 2-domain of T cell-specific

4 totally unrelated late domain sequences from Rous sarcoma virus (contained in its p2b sequence) or eq

5 is virus integrase and bacterial recombinant Rous sarcoma virus (Prague A strain) integrase (approxim

6 resolution of a fragment of the integrase of Rous sarcoma virus (residues 49-286) containing both the

7 In particular, although both Rous sarcoma virus (RSV) and AMV could replicate in cult

8 ze budding of virus-like particles (VLPs) of Rous sarcoma virus (RSV) and HIV type 1 (HIV-1).

9 membrane binding, we fused the MA domains of Rous sarcoma virus (RSV) and HIV-1 to the chemically ind

10 the Gag protein; however, recent studies of Rous sarcoma virus (RSV) and human immunodeficiency viru

11 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

12 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

13 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

14 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

15 immunodeficiency virus type 1 (HIV-1) and of Rous sarcoma virus (RSV) are morphologically distinct wh

16 ssed this question using the alpharetrovirus Rous sarcoma virus (RSV) as a model system.

17 onducted to investigate the initial steps of Rous sarcoma virus (RSV) assembly by examining the assoc

18 Rous sarcoma virus (RSV) budding requires an interaction

19 The first few residues of the Rous sarcoma virus (RSV) CA protein comprise a structura

20 of charged residues in the FL region of the Rous sarcoma virus (RSV) CA to particle assembly.

21 d-state NMR (ssNMR) resonance assignments of Rous sarcoma virus (RSV) CA, assembled into hexamer tube

22 sembly incompetent by testing the ability of Rous sarcoma virus (RSV) CA-SP to assemble in vitro into

23 variety of specimens assembled in vitro from Rous sarcoma virus (RSV) CA.

24 The Gag protein of Rous sarcoma virus (RSV) can direct particle assembly an

25 structure of the N-terminal domain (NTD) of Rous sarcoma virus (RSV) capsid protein (CA), with an up

26 During virion maturation, the Rous sarcoma virus (RSV) capsid protein is cleaved from

27 an immunodeficiency virus type 1 (HIV-1) and Rous sarcoma virus (RSV) capsid proteins form a beta-hai

28 The cellular receptor for subgroup A Rous sarcoma virus (RSV) contains a single LDL-A module

29 ence appears to be modular, as the unrelated Rous sarcoma virus (RSV) Env can be made Vpu sensitive b

30 We have previously described a mutant Rous sarcoma virus (RSV) Env protein, Env-mu26, with an

31 this model, CA proteins from both HIV-1 and Rous sarcoma virus (RSV) form similar hexagonal lattices

32 We have identified an assembly-defective Rous sarcoma virus (RSV) Gag mutant that retains signifi

33 Rous sarcoma virus (RSV) Gag nuclear cycling is a unique

34 tudy in vitro-assembled, immature virus-like Rous sarcoma virus (RSV) Gag particles and have determin

35 triphosphate [PI(3,4,5)P(3)] levels impaired Rous sarcoma virus (RSV) Gag PM localization.

36 The p2 region of the Rous sarcoma virus (RSV) Gag polyprotein contains an ass

37 Nucleocytoplasmic shuttling of the Rous sarcoma virus (RSV) Gag polyprotein is an integral

38 The Rous sarcoma virus (RSV) Gag polyprotein undergoes trans

39 The Rous sarcoma virus (RSV) Gag precursor polyprotein is th

40 Proteolytic processing of the Rous sarcoma virus (RSV) Gag precursor was altered in vi

41 of the NC domain in assembly of VLPs from a Rous sarcoma virus (RSV) Gag protein and have characteri

42 We have purified Rous sarcoma virus (RSV) Gag protein and in parallel sev

43 The first 86 residues of the Rous sarcoma virus (RSV) Gag protein form a membrane-bin

44 ously reported that nuclear transport of the Rous sarcoma virus (RSV) Gag protein is intrinsic to the

45 med spontaneously in vitro from fragments of Rous sarcoma virus (RSV) Gag protein purified after expr

46 ped three very small, modular regions of the Rous sarcoma virus (RSV) Gag protein that are necessary

47 We discovered that the Rous sarcoma virus (RSV) Gag protein transiently localiz

48 red that the oncogenic avian alpharetrovirus Rous sarcoma virus (RSV) Gag protein undergoes transient

49 In the Rous sarcoma virus (RSV) Gag protein, the 25 amino-acid

50 In the Rous sarcoma virus (RSV) Gag protein, the M domain is co

51 een these two hypotheses, we made use of the Rous sarcoma virus (RSV) Gag protein, the PR of RSV IS i

52 erminal 100 residues of the non-myristylated Rous sarcoma virus (RSV) Gag protein.

53 We used Rous sarcoma virus (RSV) Gag together with membrane sens

54 eption was the 11-amino-acid p2b sequence of Rous sarcoma virus (RSV) Gag, which could fully restore

55 essential steps in understanding the chicken Rous sarcoma virus (RSV) genome association with a nonpe

56 elatively short, 82 nucleotide region of the Rous sarcoma virus (RSV) genome, called muPsi, was shown

57 Uniquely, the simple retrovirus Rous sarcoma virus (RSV) has a Gag structural protein th

58 The major late domain of Rous sarcoma virus (RSV) has been mapped to a PPPY motif

59 The L domain of Rous sarcoma virus (RSV) has been shown to interact with

60 t, the L domains of oncoretroviruses such as Rous sarcoma virus (RSV) have a more N-terminal location

61 We produced kinetically stabilized Rous sarcoma virus (RSV) intasomes with human immunodefi

62 Site-directed mutagenesis of recombinant Rous sarcoma virus (RSV) integrase (IN) allowed us to ga

63 nhanced when the serine at amino acid 124 of Rous sarcoma virus (RSV) integrase is replaced by alanin

64 The Rous sarcoma virus (RSV) is an exception, in that its ge

65 About one-third of the MA protein in Rous sarcoma virus (RSV) is phosphorylated.

66 we have examined whether the alpharetrovirus Rous sarcoma virus (RSV) is susceptible to inhibition by

67 proteins that specifically interact with the Rous sarcoma virus (RSV) L domain in vitro and in vivo.

68 The discovery of Rous sarcoma virus (RSV) led to the identification of ce

69 taining the ts gene under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

70 dogenous AAV promoters, p5 and p40, with the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

71 eracts with the Schmidt-Ruppin strain of the Rous sarcoma virus (RSV) long terminal repeat (LTR) betw

72 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

73 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

74 CC-3' present on the noncoding strand of the Rous sarcoma virus (RSV) long terminal repeat (LTR) in a

75 eceptor (ecoR) cDNA under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) prom

76 alovirus (CMV) immediate-early promoter, the Rous sarcoma virus (RSV) long terminal repeat, and the a

77 ts within the avian leukosis virus (ALV) and Rous sarcoma virus (RSV) LTR enhancers in a pattern iden

78 ssociation of HIV-1 Gag, as well as purified Rous sarcoma virus (RSV) MA and Gag, depends strongly on

79 in vitro flotation assay to directly measure Rous sarcoma virus (RSV) MA-membrane interaction in the

80 rted repeat (IR) within the U5 region of the Rous sarcoma virus (RSV) mRNA forms a structure composed

81 In this report, a Rous sarcoma virus (RSV) mutant having two acidic-to-bas

82 The Rous sarcoma virus (RSV) negative regulator of splicing

83 135-nucleotide (nt) direct repeats flank the Rous sarcoma virus (RSV) oncogene src and are composed o

84 virus-based vector LNCX, contain an internal Rous sarcoma virus (RSV) or cytomegalovirus (CMV) promot

85 ctivity compared with strong but nonspecific rous sarcoma virus (RSV) or cytomegalovirus promoters.

86 The late assembly domain (L-domain) of Rous sarcoma virus (RSV) or human immunodeficiency virus

87 virus (EIAV) is functionally homologous with Rous sarcoma virus (RSV) p2b and human immunodeficiency

88 ent of Gag in in vivo and in vitro assembled Rous sarcoma virus (RSV) particles and to compare these

89 However, in the presence of budding HIV-1 or Rous sarcoma virus (RSV) particles, some glycoproteins,

90 The Rous sarcoma virus (RSV) polyadenylation site (PAS) is v

91 mmunodeficiency virus type 1 (HIV-1) PTAP or Rous sarcoma virus (RSV) PPPY L domain in the p9 protein

92 t the enzymatic and structural properties of Rous sarcoma virus (RSV) PR are exquisitely sensitive to

93 pHyde gene under the control of a truncated Rous sarcoma virus (RSV) promoter (AdRSVpHyde) was gener

94 he cDNA for human iNOS was cloned behind the Rous sarcoma virus (RSV) promoter to create adenovirus (

95 Rous sarcoma virus (RSV) promoter-driven expression of t

96 novirus containing the HERG gene driven by a Rous sarcoma virus (RSV) promoter.

97 ontrol of the human cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoters.

98 enzyme, resulting in a highly active mutant Rous sarcoma virus (RSV) protease that displays many cha

99 ld be initiated by electroporation of cloned Rous sarcoma virus (RSV) proviral DNA into the developin

100 Expression of the Gag-Pol polyprotein of Rous sarcoma virus (RSV) requires a -1 ribosomal framesh

101 Rous sarcoma virus (RSV) requires large amounts of unspl

102 We asked whether a single Rous sarcoma virus (RSV) RNA can be translated and subse

103 The 5' untranslated region of Rous sarcoma virus (RSV) RNA is a highly ordered structu

104 inding site in the 5' untranslated region of Rous sarcoma virus (RSV) RNA play an integral role in mu

105 ing element in the 3' untranslated region of Rous sarcoma virus (RSV) RNA was found to promote Rev-in

106 We previously identified the Rous sarcoma virus (RSV) stability element (RSE), an RNA

107 the single-particle cryo-EM structure of the Rous sarcoma virus (RSV) strand transfer complex (STC) i

108 a mouse monoclonal antibody directed against Rous sarcoma virus (RSV) subgroup A Env that will be use

109 produce milligram quantities of the soluble Rous sarcoma virus (RSV) synaptic complex that is kineti

110 describes new mutations in the CA protein of Rous sarcoma virus (RSV) that were designed to test whet

111 In chick embryo fibroblasts transformed by Rous sarcoma virus (RSV) the tyrosine phosphorylation of

112 V), feline immunodeficiency virus (FIV), and Rous sarcoma virus (RSV) to critically address the role

113 The Rous sarcoma virus (RSV) transmembrane (TM) glycoprotein

114 ne transport, the multidomain Gag protein of Rous sarcoma virus (RSV) undergoes importin-mediated nuc

115 RNA(Lys3) as the replication primer, whereas Rous sarcoma virus (RSV) uses tRNA(Trp).

116 discovery from Ray Erikson's group that the Rous sarcoma virus (RSV) v-Src-transforming protein had

117 ol vector containing a constitutively active Rous sarcoma virus (RSV) viral promoter driving the luci

118 A PPPPY motif within the L domain of Rous sarcoma virus (RSV) was previously characterized as

119 y reactions with purified CA proteins of the Rous sarcoma virus (RSV) were used to define factors tha

120 We previously reported that a mutant Rous sarcoma virus (RSV) with an alternate polypurine tr

121 t here that IP6 is also used for assembly of Rous sarcoma virus (RSV), a retrovirus from a different

122 Rous sarcoma virus (RSV), a simple retrovirus, needs to

123 resembles the PPPPY motif in the L domain of Rous sarcoma virus (RSV), an avian retrovirus.

124 HIV-1, Moloney murine leukemia virus (MLV), Rous sarcoma virus (RSV), and human T-cell lymphotropic

125 human immunodeficiency virus type 1 (HIV-1), Rous sarcoma virus (RSV), and Mason-Pfizer monkey virus

126 articles of the prototypic avian retrovirus, Rous sarcoma virus (RSV), by using scanning transmission

127 In some orthoretroviruses, including Rous Sarcoma Virus (RSV), CA carries a short and hydroph

128 ton Rous recovered a virus, now known as the Rous sarcoma virus (RSV), from a chicken sarcoma, which

129 For Rous sarcoma virus (RSV), Gag proteins are synthesized i

130 osed based on the existence of MA mutants in Rous sarcoma virus (RSV), murine leukemia virus, human i

131 During assembly and morphogenesis of Rous sarcoma virus (RSV), proteolytic processing of the

132 For Rous sarcoma virus (RSV), the size determinant maps to t

133 In the case of Rous sarcoma virus (RSV), the size determinant maps to t

134 In prior studies of the retrovirus Rous sarcoma virus (RSV), we observed that the Gag prote

135 , a Gammaretrovirus, and the Alpharetrovirus Rous sarcoma virus (RSV), were susceptible to inhibition

136 eplication-competent shuttle vector based on Rous sarcoma virus (RSV), with alternate retroviral PPTs

137 the utility of the system, we developed new Rous sarcoma virus (RSV)-based replication-incompetent v

138 tween the PBS and the CA dinucleotide of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z to matc

139 the endogenous polypurine tract (PPT) of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z was rep

140 ions in the 5' end of the U3 sequence of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z.

141 stablishment of the transformed phenotype in Rous sarcoma virus (RSV)-infected cells.

142 eplication-defective adenoviral vectors [Adv.Rous sarcoma virus (RSV)-nf] representing three families

143 vector encoding a peptide inhibitor of PKA [Rous sarcoma virus (RSV)-protein kinase A inhibitor (PKI

144 Rous sarcoma virus (RSV)-tk bearing the HSV1-tk gene wer

145 the robustly induced enzymatic activities in Rous sarcoma virus (RSV)-transformed chicken cells.

146 tures found in osteoclasts, macrophages, and Rous sarcoma virus (RSV)-transformed fibroblasts.

147 ng a well-established retroviral model-avian Rous sarcoma virus (RSV)-we analyzed changes in an RSV v

148 icken embryo fibroblasts (CEF) infected with Rous sarcoma virus (RSV).

149 odel retroviral envelope protein (EnvA) from Rous sarcoma virus (RSV).

150 +)-ATPase (SERCA2a) under the control of the Rous sarcoma virus (RSV).

151 ric interactions between the Gag proteins of Rous sarcoma virus (RSV).

152 ansforming viral oncogene product encoded by Rous sarcoma virus (RSV).

153 d CRM1-dependent nuclear cycling was that of Rous sarcoma virus (RSV).

154 -membrane interaction of the alpharetrovirus Rous sarcoma virus (RSV).

155 ecades of study on an avian RNA tumor virus, Rous sarcoma virus (RSV).

156 iruses containing the cellular receptors for Rous sarcoma virus (Tva) or ecotropic murine leukemia vi

157 One mechanism by which Rous sarcoma virus achieves incomplete splicing involves

158 chicken embryo fibroblasts (CEF) infected by Rous sarcoma virus against a confluent background of uni

159 roviruses that undergo type C morphogenesis, Rous sarcoma virus and human immunodeficiency virus, whi

160 n the SU and TM envelope protein subunits of Rous sarcoma virus and murine leukemia virus.

161 s containing TATA and/or initiator elements, Rous sarcoma virus and thymidine kinase promoters in BeW

162 peat (DR) sequences flanking the src gene in Rous sarcoma virus are essential posttranscriptional con

163 e experiments reported here, using the avian Rous sarcoma virus as a model system, further define the

164 erve as mRNA for the envelope protein and in Rous sarcoma virus as src mRNA.

165 polyprotein are intrinsic components of the Rous sarcoma virus assembly pathway.

166 that allowed for the first-time formation of Rous sarcoma virus CA into structures resembling authent

167 Instead, the Rous sarcoma virus capsid protein contains a single cyst

168 olecular disulfide bond during assembly, the Rous sarcoma virus capsid protein does not.

169 of charged amino acids on the surface of the Rous sarcoma virus capsid protein in the assembly of app

170 ed sequence similarity, the structure of the Rous sarcoma virus capsid protein is similar to the stru

171 ences that exist in the C-terminal domain of Rous sarcoma virus capsid relative to the other capsid p

172 on of baby hamster kidney fibroblasts by the Rous sarcoma virus causes a significant increase in the

173 Since codon composition values for Rous sarcoma virus distinguished a "foreign" gene from t

174 We have examined mutant Rous sarcoma virus envelope proteins with truncations or

175 unodeficiency virus type 1, visna virus, and Rous sarcoma virus exhibited different target site prefe

176 o- deficiency virus type 1, visna virus, and Rous sarcoma virus exhibited distinct preferences for wa

177 here that while deletion of the NC domain of Rous sarcoma virus Gag abolishes formation and budding o

178 Using purified Rous sarcoma virus Gag and Gag truncations, we studied t

179 icles (VLPs), we observed that expression of Rous sarcoma virus Gag failed to produce VLPs.

180 The Rous sarcoma virus gag gene contains a cis-acting negati

181 ture of the CA domains in immature assembled Rous sarcoma virus Gag particles.

182 In the context of the Rous sarcoma virus Gag polyprotein, only the nucleocapsi

183 It was shown previously that a Rous sarcoma virus Gag protein missing only the protease

184 The Rous sarcoma virus Gag protein undergoes transient nucle

185 purified, slightly truncated version of the Rous sarcoma virus Gag protein, Delta MBD Delta PR, and

186 rescence correlation spectroscopy-to examine Rous sarcoma virus Gag-Gag and -membrane interactions in

187 gion, Mpsi, from the 5' leader region of the Rous sarcoma virus genome that is sufficient to direct t

188 ckaging signal, MPsi, from the 5' end of the Rous sarcoma virus genome.

189 0 amino acid residue capsid protein from the Rous sarcoma virus has been determined by NMR methods.

190 structure of the three-domain integrase from Rous sarcoma virus in complex with viral and target DNAs

191 contrast, CEF cultures heavily infected with Rous sarcoma virus in the same medium underwent pervasiv

192 plasmid acceptor, purified bacterium-derived Rous sarcoma virus integrase (IN), and a host cell DNA-b

193 ogous positions in visna virus integrase and Rous sarcoma virus integrase changed the target site pre

194 ous studies revealed that truncated forms of Rous sarcoma virus integrase containing two of the three

195 A direct comparison demonstrates that Rous sarcoma virus is capable of infecting aphidicolin-a

196 ct of the retroviral M domain from the avian Rous sarcoma virus is defined and its solution structure

197 Examination of the genomes of three Rous sarcoma virus isolates indicated that codon composi

198 Although the integrity of the entire Rous sarcoma virus leader sequence is important for retr

199 binding chicken Y-box protein that promotes Rous sarcoma virus long terminal repeat (RSV LTR)-driven

200 ilar to the levels observed in vivo with the Rous sarcoma virus long terminal repeat constitutive pro

201 tained human factor IX (hFIX) cDNA driven by Rous sarcoma virus long terminal repeat in the E1 region

202 antibiotic-resistance gene was driven by the Rous sarcoma virus long terminal repeat or the herpes si

203 2(1) collagen promoters and 10-fold from the Rous sarcoma virus long terminal repeat.

204 ng MyoD under transcriptional control of the Rous sarcoma virus long terminal repeat.

205 To further study the role of the Rous sarcoma virus MA sequence in the viral replication

206 us, all of the functions associated with the Rous sarcoma virus MA sequence must be contained within

207 o -90 confers FGF2/FSK responsiveness on the Rous sarcoma virus minimal promoter.

208 In vivo screening of Rous sarcoma virus mutants was performed with randomly m

209 the site phosphorylated by gamma-PAK in the Rous sarcoma virus nucleocapsid protein NC in vivo and i

210 ngeable late assembly domains carried by the Rous sarcoma virus p2b protein and human immunodeficienc

211 , human immunodeficiency virus type 1 p6, or Rous sarcoma virus p2b.

212 er of cis-acting sequences within the RNA of Rous sarcoma virus play a role in preserving a large poo

213 Rous sarcoma virus pre-mRNA contains an element known as

214 coli lacZ reporter gene under control of the Rous sarcoma virus promoter and mammalian RNA processing

215 cloned into a pMAMneo vector containing the Rous sarcoma virus promoter and the neomycin resistance

216 r carrying the cDNA for C/EBPalpha driven by Rous sarcoma virus promoter elements (AdCEBPalpha) or a

217 which sig-mEndo expression was driven by the Rous sarcoma virus promoter had moderately high serum le

218 ls from the beta-galactosidase gene when the Rous sarcoma virus promoter is used to drive transgene e

219 riptional control of a constitutively active Rous sarcoma virus promoter was regulated identically to

220 endogenously expressing SDF-1/CXCL12 under a Rous sarcoma virus promoter were produced.

221 as an inducible HIV-1 genome controlled by a Rous sarcoma virus promoter with lac operator sequences.

222 porter beta-galactosidase gene driven by the Rous Sarcoma Virus promoter.

223 HIT, and CHO cells using cytomegalovirus or Rous sarcoma virus promoters.

224 The Rous sarcoma virus protease displays a high degree of sp

225 Other substrates such as the Rous sarcoma virus protein NC are phosphorylated by gamm

226 ervative substitutions in this region of the Rous sarcoma virus protein were lethal due to a severe d

227 f a weak src 3'ss is necessary for efficient Rous sarcoma virus replication.

228 Cell transformation by Rous sarcoma virus results in a dramatic change of adhes

229 Rous sarcoma virus RNA contains a negative regulator of

230 Accumulation of unspliced Rous sarcoma virus RNA is facilitated in part by a negat

231 only 2.6-fold less efficiently than genomic Rous sarcoma virus RNA.

232 downstream from the 3'ss of the heterologous Rous sarcoma virus src gene.

233 e 3' splice site in the BPV-1 late pre-mRNA, Rous sarcoma virus src pre-mRNA, human immunodeficiency

234 As also found for other retroviruses, the Rous sarcoma virus structural protein Gag is necessary a

235 he negative regulator of splicing (NRS) from Rous sarcoma virus suppresses viral RNA splicing and is

236 ng (NRS) is a long cis-acting RNA element in Rous sarcoma virus that contributes to unspliced RNA acc

237 a mutant of the viral matrix (MA) protein of Rous sarcoma virus that disrupts viral RNA dimerization.

238 to as antisense, can inhibit replication of Rous sarcoma virus through hybridization to viral RNA.

239 We find that Rous sarcoma virus virions, like the human immunodeficie

240 by his discovery of reverse transcriptase in Rous sarcoma virus virions.

241 By cryoelectron tomography, Rous sarcoma virus VLPs show an organized hexameric latt

242 natural or mutated 5' leader sequences from Rous sarcoma virus were expressed in avian cells in the

243 the cell dramatically reduced the release of Rous sarcoma virus, an avian retrovirus.

244 Tva is the receptor for subgroup A Rous sarcoma virus, and it contains a single LDL-A modul

245 quenced a small segment of the 3' end of the Rous sarcoma virus, just inside the poly(A) tail, at the

246 of four promoters (dihydrofolate reductase, Rous sarcoma virus, long terminal repeat, or cytomegalov

247 In Rous sarcoma virus, previous studies have identified imp

248 from human immunodeficiency virus type 1 or Rous sarcoma virus, respectively.

249 In Rous sarcoma virus, splicing control is achieved in part

250 gate Gag protein structure and processing in Rous sarcoma virus, the prototype of the avian sarcoma a

251 e used cryo-electron tomography to visualize Rous sarcoma virus, the prototypic alpharetrovirus.

252 e-bound nonreceptor tyrosine kinase Src from Rous sarcoma virus, these interactions are mediated by a

253 In HIV-1 and Rous sarcoma virus, this region forms a rod-like structu

254 ses, including the prototypic oncoretrovirus Rous sarcoma virus, were synthesized on cytosolic riboso

255 The discovery of Rous sarcoma virus, which was reported by Peyton Rous in

256 We have constructed and characterized a Rous sarcoma virus-based retroviral vector with the host

257 Using the Rous sarcoma virus-derived vector RCAS, we previously sh

258 is tyrosine-phosphorylated when expressed in Rous sarcoma virus-infected chicken embryo fibroblasts (

259 1 is shown to transcriptionally activate the Rous sarcoma virus-long terminal repeat promoter, which

260 nducible, constitutively expressed reporter, Rous sarcoma virus-luciferase (RSV-LUC); nor does it blo

261 initially identified as a phosphoprotein in Rous sarcoma virus-transformed cells.

262 HT29, and CaCo2) compared with a nonspecific Rous sarcoma virus-yCD virus.

263 domain that is present in the Gag protein of Rous sarcoma virus.

264 dentified in the gag-specific protein p2b of Rous sarcoma virus.

265 homologue of v-src, the transforming gene of Rous Sarcoma virus.

266 ch controls fibroblast transformation by the Rous sarcoma virus.

267 ive regulator of splicing (NRS) element from Rous sarcoma virus.

268 ng stimulatory element was discovered in the Rous sarcoma virus.

269 nalyses of two in-vitro-assembled capsids of Rous sarcoma virus.

270 that of the naturally nonmyristoylated MA of Rous sarcoma virus.

271 1) and 2, simian immunodeficiency virus, and Rous sarcoma virus.